Table 2.
The linked and convergent substitutions of Ebola viruses emerged during human infection.
| Number | Site | Type | Former | Latter | 18791 |
18797 |
18889 |
C stains (5512–5631)h | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 12 | Day 20 | Figure | Day 9 | Day 14 | Day 17 | Figure | Day 5 | Day 7 | Figure | ||||||
| 1 | 1958 | NP(S497P)a | T | C | 0.01b | 289.00b | 1c | 0.01 | 207.00 | 1000.00e | 1 | 1103.31 | 660.36 | 0d | 8/8 |
| 2 | 2370 | NP(A634V) | C | T | 0.00 | 48.50 | 1 | 0.00 | 2.82 | N/Af | 1 | 4.89 | 76.14 | 1 | 8/8 |
| 3 | 4384 | VP35–VP40g | A | T | 0.00 | 26.08 | 1 | 0.00 | 2.11 | 17.27 | 1 | 2.04 | 28.00 | 1 | 7/8 |
| 4 | 5512 | VP40~GP | T | C | 0.00 | 865.00 | 1 | 0.00 | 3.06 | 76.20 | 1 | 4.21 | 346.40 | 1 | 7/8 |
| 5 | 5519 | VP40~GP | T | C | 0.00 | 43.50 | 1 | 0.00 | 2.22 | 26.00 | 1 | 3.90 | 48.13 | 1 | 8/8 |
| 6 | 5522 | VP40~GP | T | C | 0.00 | 23.24 | 1 | 0.00 | 2.47 | 35.00 | 1 | 4.19 | 38.47 | 1 | 8/8 |
| 7 | 5523 | VP40~GP | T | C | 0.00 | 135.33 | 1 | 0.00 | 2.50 | 69.80 | 1 | 4.25 | 516.36 | 1 | 8/8 |
| 8 | 5548 | VP40~GP | G | A | 0.02 | 873.00 | 1 | 0.01 | 92.50 | 347.00 | 1 | 431.71 | 631.98 | 0 | 8/8 |
| 9 | 5553 | VP40~GP | T | C | 0.00 | 137.83 | 1 | 0.00 | 3.38 | 108.33 | 1 | 5.47 | 388.47 | 1 | 8/8 |
| 10 | 5566 | VP40~GP | T | C | 0.00 | 199.50 | 1 | 0.00 | 2.94 | 150.00 | 1 | 5.43 | 195.73 | 1 | 8/8 |
| 11 | 5587 | VP40~GP | T | C | 0.00 | 43.67 | 1 | 0.00 | 3.07 | 1000.00 | 1 | 5.68 | 75.12 | 1 | 8/8 |
| 12 | 5594 | VP40~GP | T | C | 0.00 | 231.00 | 1 | 0.01 | 2.13 | 121.00 | 1 | 5.36 | 344.04 | 1 | 8/8 |
| 13 | 5595 | VP40~GP | T | C | 0.00 | 59.17 | 1 | 0.00 | 1.82 | 49.40 | 1 | 5.16 | 172.81 | 1 | 8/8 |
| 14 | 5596 | VP40~GP | T | C | 0.00 | 92.00 | 1 | 0.00 | 1.76 | 27.78 | 1 | 5.06 | 79.54 | 1 | 8/8 |
| 15 | 5604 | VP40~GP | T | C | 0.00 | 140.50 | 1 | 0.00 | 2.35 | 37.00 | 1 | 6.12 | 468.33 | 1 | 8/8 |
| 16 | 5616 | VP40~GP | T | C | 0.00 | 40.62 | 1 | 0.00 | 2.87 | 59.40 | 1 | 5.70 | 67.39 | 1 | 8/8 |
| 17 | 5631 | VP40~GP | T | C | 0.00 | 119.00 | 1 | 0.01 | 2.56 | 103.33 | 1 | 5.77 | 315.38 | 1 | 8/8 |
| 18 | 5849 | VP40~GP | T | C | 190.00 | 85.00 | 0d | 163.22 | 3.20 | 44.91 | 0 | 3.74 | 137.60 | 1 | 8/8 |
| 19 | 5880 | VP40~GP | C | T | 0.00 | 161.70 | 1 | 0.00 | 2.14 | 113.29 | 1 | 2.08 | 441.73 | 1 | 7/8 |
| 20 | 7267 | GP(R410S) | T | A | 0.00 | N/A | N/A | 0.00 | 57.00 | 1000.00 | 1 | 1281.65 | 2044.63 | 0 | 0/8 |
| 21 | 7352 | GP(E439K) | G | A | 0.03 | N/A | N/A | 0.03 | 17.33 | 1000.00 | 1 | 1102.30 | 495.67 | 0 | 8/8 |
| 22 | 8044 | GP(F669F) | C | T | 0.00 | 3.55 | 1 | 0.00 | 2.87 | 24.68 | 1 | 3.60 | 225.08 | 1 | 7/8 |
| 23 | 9426 | VP30–VP24 | C | T | 0.01 | 1000.00 | 1 | 0.01 | 1000.00 | 1000.00 | 1 | 792.13 | 473.41 | 0 | 8/8 |
| 24 | 10133 | VP30–VP24 | T | Del | 0.00 | 1000.00 | 1 | 0.01 | 0.97 | 3.95 | 1 | 1.65 | 7.45 | 1 | 6/8 |
| 25 | 10273 | VP30–VP24 | G | A | 0.11 | 116.00 | 1 | 0.12 | 173.00 | 202.50 | 1 | 330.20 | 317.62 | 0 | 8/8 |
| 26 | 10431 | VP24(F29F) | C | T | 0.00 | 30.33 | 1 | 0.00 | 2.91 | 125.67 | 1 | 2.70 | 321.75 | 1 | 7/8 |
| 27 | 10466 | VP24(Y41C) | A | G | 0.00 | 28.33 | 1 | 0.00 | 2.11 | 50.57 | 1 | 2.53 | 382.21 | 1 | 7/8 |
| 28 | 11407 | VP24~L | C | T | 113.88 | N/A | N/A | 133.23 | 1.86 | 17.14 | 0 | 2.44 | 91.21 | 1 | 8/8 |
| 29 | 13350 | L(END591Q) | T | C | 0.00 | N/A | N/A | 0.00 | 16.24 | 72.00 | 1 | 17.68 | 321.12 | 1 | 7/8 |
| 30 | 13557 | L(E657K) | G | A | 0.00 | N/A | N/A | 0.00 | 13.98 | 71.33 | 1 | 16.96 | 466.17 | 1 | 7/8 |
| 31 | 15048 | L(L1157P) | T | C | 0.01 | N/A | N/A | 0.01 | 1000.00 | 219.33 | 1 | 1216.72 | 937.44 | 0 | 8/8 |
| 32 | 15226 | L(P1216P) | T | C | 0.00 | N/A | N/A | 0.00 | 3.49 | 34.14 | 1 | 3.91 | 90.47 | 1 | 7/8 |
| 33 | 16894 | L(A1773T) | G | A | 0.00 | 34.50 | 1 | 0.00 | 77.00 | 74.25 | 1 | 93.06 | 61.84 | 0 | 8/8 |
| 34 | 18078 | L(H2187H) | T | C | 0.00 | 16.50 | 1 | 0.00 | 1.75 | N/A | 1 | 2.68 | 23.47 | 1 | 8/8 |
| 35 | 18319 | 5′-UTR | T | C | 0.00 | 9.00 | 1 | 0.00 | 2.35 | N/A | 1 | 2.64 | 27.41 | 1 | 8/8 |
The nonsynonymous mutations are emphasized by bold fonts.
The ratio of the reads of Latter/Former.
“1” means that the corresponding data of the survivor was shown in Figure 4B–D.
“0” means that the corresponding data of the survivor was shown in Supplementary Figure S1.
The ratio is termed as “1000” when the read of the former nucleotide is 0.
“N/A” means that the reading depths of the NGS was lower than 50.
“VP35–VP40” means that the substitutions locate in the non-coding region between VP35 and VP40.
“C stains (5512–5631)” indicate the 8 stains from publicly released full-length EBOV genome sequences from GenBank, including KT961624, KP759706, KU296370, KU296319, LN877955, KT357858, KT357859 and KT357860. These 8 strains possess the short stretch of T>C mutations within positions 5512–5631. Furthermore, these strains also have the linked mutations in other sites. The proportions of the strains which possess the mutations were shown in fractions.